<DOC>
	<DOCNO>NCT00005867</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . It yet know regimen combination chemotherapy effective non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study two regimen combination chemotherapy compare well work treat patient aggressive non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival , failure free survival , disease specific survival , relapse free survival , response rate patient aggressive non-Hodgkin 's lymphoma treat mitoxantrone , cyclophosphamide , etoposide , vincristine , bleomycin , prednisolone ( PMitCEBO ) versus cyclophosphamide , doxorubicin , vincristine , prednisolone ( CHOP ) . - Compare early late toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive mitoxantrone IV , cyclophosphamide IV , etoposide IV day 1 vincristine bleomycin IV day 8 . Treatment continue every 14 day maximum 8 course absence disease progression unacceptable toxicity . Patients also receive oral prednisolone daily course 1 2 every day begin course 3 continue end treatment . - Arm II : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 oral prednisolone day 1-5 . Treatment continue every 21 day maximum 8 course absence disease progression unacceptable toxicity . Patients follow 4 week , every 3 month 1 year , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 310 patient ( 155 per arm ) accrue study 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously untreated bulky stage IA stage IBIV aggressive nonHodgkin 's lymphoma 1 follow type : Working formulation : Follicular large cell Diffuse mix cell Diffuse large cell Diffuse immunoblastic OR REAL classification : Diffuse large Bcell Peripheral Tcell Measurable evaluable disease Good prognosis define one following : Stage III/IV disease LDH great upper limit normal ECOG/WHO 24 No lymphoblastic Burkitt 's lymphoma No CNS involvement PATIENT CHARACTERISTICS : Age : 18 59 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : Hemoglobin least 10 g/dL Neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin , AST , ALT great 1.5 time upper limit normal Renal : Creatinine great 1.7 mg/dL Cardiovascular : Ejection fraction least 50 % unless dysfunction attributable lymphoma Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent serious uncontrolled medical condition No prior malignancy except adequately treat nonmelanoma skin cancer cervical intraepithelial neoplasia PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 35 % hematopoietic site Concurrent consolidation radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
</DOC>